Patents Represented by Attorney Leroy Whitaker
  • Patent number: 5252566
    Abstract: Thrombin inhibitors represented by the formula ##STR1## as provided wherein A is e.g. phenylglycyl, and phenylalanyl, .alpha.-methylphenylalanine and .alpha.-methylphenylglycine wherein the amino group is preferably substituted with lower alkyl alkanoyl or lower alkoxycarbonyl, or a bicyclo group e.g. 1,2,3,4-tetrahydroisoquinolin-1-yl. Also provided are a method for inhibiting clot formation in man and animals, pharmaceutical formulations useful in the method and intermediates for the inhibitors.
    Type: Grant
    Filed: October 16, 1992
    Date of Patent: October 12, 1993
    Assignee: Eli Lilly and Company
    Inventor: Robert T. Shuman
  • Patent number: 5252756
    Abstract: A stereoselective process for preparing 2-deoxy-2,2-difluoro-D-ribofuranosyl beta-anomer enriched aryl sulfonates or substituted arylsulfonates involving reacting a lactol with an acid scavenger and a sulfonating reagent in an inert solvent.
    Type: Grant
    Filed: June 22, 1992
    Date of Patent: October 12, 1993
    Assignee: Eli Lilly and Company
    Inventors: Ta-Sen Chou, Charles D. Jones
  • Patent number: 5250539
    Abstract: The invention relates to 1,2,3,4,5,6-hexahydrobenzo[f]quinolin-3-ones, pharmaceutical formulations containing those compounds, and their use as steroid 5.alpha.-reductase inhibitors.
    Type: Grant
    Filed: October 21, 1991
    Date of Patent: October 5, 1993
    Assignee: Eli Lilly and Company
    Inventors: Kenneth S. Hirsch, Charles D. Jones
  • Patent number: 5250542
    Abstract: 3,4,4-trisubstitutedpiperidinyl-N-alkylcarboxylates and intermediates for their preparation are provided. These piperidine-N-alkylcarboxylates are useful as peripheral opioid antagonists.
    Type: Grant
    Filed: July 17, 1992
    Date of Patent: October 5, 1993
    Assignee: Eli Lilly and Company
    Inventors: Buddy E. Cantrell, Dennis M. Zimmerman
  • Patent number: 5250572
    Abstract: The present invention provides (R)-norfluoxetine and pharmaceutically acceptable salts thereof capable of selectively occupying 5HT.sub.1c receptors.
    Type: Grant
    Filed: April 21, 1992
    Date of Patent: October 5, 1993
    Assignee: Eli Lilly and Company
    Inventors: David W. Robertson, David T. Wong
  • Patent number: 5250660
    Abstract: Tripeptides, D-Phe-L-Pro-L-Arg-H, D-Phg-L-Pro-L-Arg-H and related compounds are purified in a process comprising 1) HPLC chromatography over an alkylsilane resin and elution with a gradient comprising an organic phase of between about 2% and about 40% of acetonitrile in an aqueous acidic phase containing an inorganic acid e.g. H.sub.2 SO.sub.4 and HCl, at a pH between about 2 and about 3, and 2) adjusting the pH of the acidic eluate with a water insoluble basic ion-exchange resin to about 4 to about 6.5. The purified peptides are useful antithrombotic agents.
    Type: Grant
    Filed: November 12, 1991
    Date of Patent: October 5, 1993
    Assignee: Eli Lilly and Company
    Inventor: Robert T. Shuman
  • Patent number: 5250571
    Abstract: The present invention provides (S)-norfluoxetine and pharmaceutically acceptable salts thereof capable of inhibiting the uptake of serotonin.
    Type: Grant
    Filed: April 21, 1992
    Date of Patent: October 5, 1993
    Assignee: Eli Lilly and Company
    Inventors: Ray W. Fuller, David Mitchell, David W. Robertson, Gregory A. Stephenson, David T. Wong
  • Patent number: 5250676
    Abstract: Provided is a process for diastereoselectively preparing compounds of the formula ##STR1## which includes the step of subjecting a compound of the formula ##STR2## to a salt whose anion is a nucleophilic base whose conjugate acid has a pKa in the range of between about -7 to about 14, or a silylated derivative of the salt; whereinR.sub.1 is said nucleophile;R is hydrogen, or protected amino,R.sub.2 is R.sub.4 as defined herein below;R.sub.3 is a leaving group; andR.sub.4 is hydrogen, C.sub.1 -C.sub.6 alkyl, or a group of the formula--CH.sub.2 --CH.sub.2 --R.sub.6whereinR.sub.6 is 2-furyl, naphthyl, phenyl, phenyl substituted with 1, 2 or 3 substituents selected from C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylthio, nitro, halo, carboxy and amido; orR.sub.6 is a group of the formula--COOR.sub.7or--COSR.sub.7in whichR.sub.7 is selected from C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, benzyl, phenyl, or benzyl or phenyl substituted with 1, 2 or 3 substituents selected from C.sub.
    Type: Grant
    Filed: March 23, 1992
    Date of Patent: October 5, 1993
    Assignee: University of Notre Dame du Lac
    Inventors: Catherine M. Gasparski, Marvin J. Miller, Min Teng
  • Patent number: 5248691
    Abstract: This invention provides novel furanoindoline compounds effective in inhibiting the growth of solid tumors.
    Type: Grant
    Filed: September 3, 1992
    Date of Patent: September 28, 1993
    Assignee: Eli Lilly and Company
    Inventor: Fariborz Mohamadi
  • Patent number: 5247073
    Abstract: The present invention provides compounds of the formula ##STR1## wherein R.sup.0 is amino or protected amino; A and A' are taken together form a group of the formulae ##STR2## wherein X is hydrogen, halo, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkoxycarbonyl, amino, nitro, carboxy; and Y is nitrogen; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 2, 1992
    Date of Patent: September 21, 1993
    Assignee: Eli Lilly and Company
    Inventor: Robert J. Ternansky
  • Patent number: 5244912
    Abstract: 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[cd]indoles are provided which are useful in modifying the function of serotonin in mammals.
    Type: Grant
    Filed: March 28, 1991
    Date of Patent: September 14, 1993
    Assignee: Eli Lilly and Company
    Inventors: Richard N. Booher, David E. Lawhorn, Charles J. Paget, Jr., John M. Schaus
  • Patent number: 5244806
    Abstract: The invention discloses modified forms of the enzyme tissue plasminogen activator (t-PA) in which recombinant DNA techniques are utilized to modify the structure of the t-PA cDNA to express a modified t-PA which retains the ability to activate plasminogen yet binds less efficiently to plasmin inhibitor. The invention provides novel DNA compounds and recombinant DNA expression vectors that encode modified human t-PA wherein all or a portion of the kringle protein domains of native human t-PA are removed. Both eukaryotic and prokaryotic expression vectors containing the modified t-PA DNA have been constructed and used to transform Chinese hamster ovary cells and Escherichia coli cells.
    Type: Grant
    Filed: November 19, 1990
    Date of Patent: September 14, 1993
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Sheila P. Little, Brigitte E. Schoner, Barbara J. Weigel
  • Patent number: 5244911
    Abstract: 6-Heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[cd]indoles are provided which are useful in modifying the function of serotonin in mammals.
    Type: Grant
    Filed: March 28, 1991
    Date of Patent: September 14, 1993
    Assignee: Eli Lilly and Company
    Inventors: Richard N. Booher, David E. Lawhorn, Michael J. Martinelli, Charles J. Paget, Jr., John M. Schaus
  • Patent number: 5242688
    Abstract: The present invention provides a method of treating thromboembolic disorders with the diglycosylated form of a tissue plasminogen activator derivative that lacks the Finger, EGF and Kringle I domains of the native tissue plasminogen activator molecule.
    Type: Grant
    Filed: December 24, 1990
    Date of Patent: September 7, 1993
    Assignee: Eli Lilly and Company
    Inventors: Philip J. Burck, Charles V. Jackson, Gerald F. Smith
  • Patent number: 5242814
    Abstract: New polyether antibiotic A80789, its acyl ester, alkyl ester, and alkyl ether derivatives, and salts thereof, are useful as antibacterial and anticoccidial agents and increase feed-utilization efficiency in animals. Methods of making A80789 by culture of Streptomyces hygroscopicus NRRL 18513, and combinations of the A80789 compounds with nicarbazin, 4,4'-dinitrocarbanilide, certain napthalenamine and benzenamine compounds and are also provided.
    Type: Grant
    Filed: May 29, 1991
    Date of Patent: September 7, 1993
    Assignee: Eli Lilly and Company
    Inventors: Raymond C. Yao, Robert L. Hamill
  • Patent number: 5243053
    Abstract: This invention provides new stabilized methylene Meldrum's acid precursors, a process for their preparation, and a process for using such compounds in the preparation of methylene Meldrum's acid.
    Type: Grant
    Filed: February 26, 1992
    Date of Patent: September 7, 1993
    Assignee: Eli Lilly and Company
    Inventor: Mohammad Zia-Ebrahimi
  • Patent number: 5239064
    Abstract: A novel antibiotic complex, A59770, individual factors and derivatives thereof, are provided. The A59770 compounds are useful as pesticides, particularly as rodenticides. Further provided are methods for reducing a rodent population, rodenticidal compositions, and an A59770-producing Amycolatopsis orientalis culture.
    Type: Grant
    Filed: April 11, 1990
    Date of Patent: August 24, 1993
    Assignee: Eli Lilly and Company
    Inventors: Marvin M. Hoehn, Karl H. Michel, Raymond C. Yao
  • Patent number: 5238959
    Abstract: The present invention provides 3-(4-substitutedphenoxy)-3-phenyl propanamines capable of inhibiting the uptake of serotonin. These compounds are useful for treating many pharmacological disorders, including depression and obesity. These compounds can also be used to reduce the desire to smoke and consume alcohol.
    Type: Grant
    Filed: April 20, 1992
    Date of Patent: August 24, 1993
    Assignee: Eli Lilly and Company
    Inventors: David W. Robertson, David T. Wong
  • Patent number: 5239069
    Abstract: The invention provides compounds of the formula ##STR1## wherein R* is a group of the formula ##STR2## wherein R and R.sup.0 are individually C.sub.1 -C.sub.6 alkyl groups or together form a ring consisting of the nitrogen atom to which they are attached and two to seven carbon atoms, said ring optionally substituted by one or more C.sub.1 -C.sub.6 alkyl and/or C.sub.1 -C.sub.6 substituted alkyl groups;Q and Q' are individually hydrogen, C.sub.1 -C.sub.6 alkyl, or when taken together form a divalent radical of the formula --CH.dbd.CH--CH.dbd.CH--;A is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 substituted alkyl, --S--(C.sub.1 -C.sub.6 alkyl)CO.sub.2 R", or --CH.sub.2 (C.sub.1 -C.sub.6 alkyl) CO.sub.2 R" wherein R"is hydrogen or a carboxy-protecting group;A' is hydrogen, an amide-protecting group, or a group of the formula --CH.sub.2 CO.sub.2 R".
    Type: Grant
    Filed: July 22, 1992
    Date of Patent: August 24, 1993
    Assignee: Eli Lilly and Company
    Inventor: Leland O. Weigel
  • Patent number: 5239075
    Abstract: This invention relates to a process for the preparation of hexa- and octahydrobenzo[f]quinolin-3-ones.
    Type: Grant
    Filed: August 10, 1992
    Date of Patent: August 24, 1993
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, David E. Lawhorn